+Advanced Search
Home > Archive>Volume 30, Issue 11, 2020 >140-145. DOI:10. 3969 / j.issn.1671-7856. 2020. 11. 023
PDF HTML XML Export Cite reminder
Research progress on the biosafety of mesenchymal stem cells
CSTR:
[cstr]
Author:
Affiliation:

Hunan Center of Drug Safety Evaluation and Research of Drugs & Hunan Key Laboratory of Pharmacodynamics and Safety Evaluation of New Drugs, Changsha 410331

  • Article
    • | |
  • Metrics
    • |
  • Reference
    • |
  • Related
    • |
  • Cited by
    • | |
  • Comments
    Abstract:

    Mesenchymal stem cells (MSCs) possess the ability to self-renew and give rise to highly differentiated cell types, and can be isolated from a wide range of sources, making them the first choice for cell therapy. MSCs are widely used in tissue repair, autoimmune diseases and degenerative diseases, and have high value. Currently, biosafety is one of the most challenging problems in the clinical translation of MSCs. Previous research on the biosafety of MSCs has been largely unclear. Therefore, we reviewed the research progress on several aspects of MSC biosafety, including genetic stability, tumorigenicity and immunogenicity. This review may provide a reference for the safety evaluation and clinical transformation of MSCs.

    Reference
    Related
    Cited by
Get Citation

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:March 15,2020
  • Online: December 25,2020
Article QR Code
You are the first Visitors
® 2025 All Rights Reserved
Address：5 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China Postcode： Phone：86-10-67779337 E-mail:bjb@cnilas.org
Supported by:Beijing E-Tiller Technology Development Co., Ltd.